GSA Capital Partners LLP Buys Shares of 25,787 iTeos Therapeutics, Inc. (NASDAQ:ITOS)

GSA Capital Partners LLP purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 25,787 shares of the company’s stock, valued at approximately $263,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of iTeos Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after buying an additional 9,660 shares in the last quarter. Dimensional Fund Advisors LP grew its position in iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after acquiring an additional 117,159 shares in the last quarter. Candriam S.C.A. acquired a new position in iTeos Therapeutics in the 2nd quarter valued at about $7,558,000. Clearline Capital LP purchased a new stake in iTeos Therapeutics during the second quarter worth about $2,328,000. Finally, Kennedy Capital Management LLC acquired a new stake in shares of iTeos Therapeutics during the first quarter worth about $1,988,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Trading Up 2.3 %

Shares of NASDAQ:ITOS opened at $8.32 on Friday. The company has a market cap of $303.93 million, a PE ratio of -2.64 and a beta of 1.39. The company’s 50 day moving average is $9.45 and its two-hundred day moving average is $13.86. iTeos Therapeutics, Inc. has a 52 week low of $7.54 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities research analysts expect that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ITOS. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Friday, November 15th. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective on the stock. JPMorgan Chase & Co. lowered their target price on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Tuesday, November 12th.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall acquired 5,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares of the company’s stock, valued at $505,766.17. This represents a 8.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.50% of the company’s stock.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.